Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — J.P. Morgan Healthcare Conference 2017
19 slides from Angiodynamics's conference presentation, Jan 10, 2017
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare ConferenceJim Clemmer, CEOMichael Greiner, CFOJanuary 10, 2017
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash fl
Slide 3: AngioDynamics Today
AngioDynamics Today 3 Leading provider of innovative medical devices used by physicians for treatment of cancer and peripheral vascular disease Focus on serving undertreated patient populations, improving patient outcomes and offering economic value to healthcare providers Operating franchises in gr
Slide 4: Three Operating Franchises
Three Operating FranchisesEach with Unique Growth Opportunities CategoriesFluid ManagementVenous InsufficiencyThrombus ManagementDrainageAngiographic CathetersKey Products Peripheral Vascular Vascular Access Oncology/Surgery CategoriesPICCsPortsDialysisKey Product CategoriesNon-Thermal AblationMicro
Slide 5: Positioned to Innovate in Changing Marketplace
Positioned to Innovate in Changing Marketplace Global Cancer Incidence To Nearly Double By 2030 $436B Global Med Tech Market by 2020 Industry growth products focus on improved patient and economic outcomes Sources: U.S. Department of Commerce International Trade Administration “2016 Top Markets Repo
Slide 6: Market Opportunity, Discipline, Product Portfolio Strategic Approach
Market Opportunity Discipline Prioritize areas where we have a competitive advantage Improve Operationally Lessen the burden on caregivers and the healthcare system Product Portfolio Strategic Approach
Slide 7: Market Opportunity and Product Portfolio
MARKET OPPORTUNITY AND PRODUCT PORTFOLIO
Slide 8: Building a Venous Disease Business
Building a Venous Disease Business Clinical Data Focused Marketing Patient Advocacy Pillars for Strategic Execution $300 Million US Varicose Vein Treatment Device Market Value (2014) 3.4 Million Annual Procedures (2015)568,500 Endovenous Ablation2,967,900 Standard Sclerotherapy Source: Millennium Re
Slide 9: Treating the Chronic Vascular Access Patient
$107M Treating the Chronic Vascular Access Patient For Patients: The BioFlo PICC demonstrated on average 87% less thrombus accumulation on its surface compared to commonly used PICCs (based on platelet count).* * Based on platelet count from in-vitro blood loop model test which may not be indicative
Slide 10: Deploying Disruptive Oncology Therapies
Deploying Disruptive Oncology Therapies Clinical Data Priority Int’l Registrations New Technology Pillars for Strategic Execution $350 Million US Interventional Oncology Device Market Value (2015) Sources: World Health Organization Cancer Fact Sheet; Millennium Research Group Medtech 360 Report. Int
Slide 11: Discipline
DISCIPLINE
Slide 12: Operational Improvements
Operational ImprovementsA Near-Term Focus to Position Company Towards Growth Capital Allocation R&D New credit facility offers enhanced flexibility for future investmentsInvestment in company through recent share repurchase Smarter product development process to unlock strategic opportunities and en
Slide 13: A Smarter Product Development Process
A Smarter Product Development Process New products currently represent ~5% of all AngioDynamics revenues, a disciplined stage gate process will unlock strategic R&D Pipeline opportunities Proposal Feasibility Development Qualification Launch Review Review Review Review Review
Slide 14: Financials
FINANCIALS
Slide 15: Historical Past Performance
Historical Past Performance Adjusted EBITDA* Sales $0.58 50.7% $0.60 50.9% Adjusted EPS* Gross Margin** * Adjusted results exclude costs relating to acquisitions, debt financing, business restructuring, litigation, credit card fees, facility consolidations, amortization of basis step-up of acquired
Slide 16: Strong Balance Sheet Drives Capital Allocation Strategy
Strong Balance Sheet Drives Capital Allocation Strategy Uses of Cash Priorities Invest internallyOpportunistically evaluate M&AExecute recently announced share buyback program authorized up to $25 million Significant cash generation, low debt and new credit facility provides flexibility to capitaliz
Slide 17: Q2'17 Financial Highlights
Q2’17 Financial Highlights Q2 FY2017 Net Sales $89.0M-0.3% yoyAdjusted EBITDA$16.1M+19% yoyAdjusted EPS$0.19+36% yoyFree Cash Flow$13.6M Key Points Improved operational performance and profitability in the quarterRaised Adjusted EPS and Cash Flow guidanceContinued to capitalize on demand driven by C
Slide 18: The Strategic Framework to Drive Growth
The Strategic Framework to Drive Growth Targeted, High-Growth Portfolio Expanded International Reach HIGH ROI INVESTMENTSMore focused R&D Program and Opportunistic M&A strategy OPERATIONAL EFFICIENCYOperational excellence across entire organization A WINNING CULTUREA culture of Accountability, Focus
Slide 19: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare ConferenceJim Clemmer, CEOMichael Greiner, CFOJanuary 10, 2017
AngioDynamics — J.P. Morgan Healthcare Conference 2017 on 6ix